Labcorp Holdings Inc. reported a notable increase in financial performance for the third quarter of 2025, with revenues reaching $3,563.5 million, an 8.6% rise from $3,282.0 million in the same period of 2024. For the nine months ending September 30, 2025, total revenues were $10,435.9 million, up 7.8% from $9,679.5 million year-over-year. The growth was attributed to organic revenue increases of 6.2% for the quarter and 4.6% for the nine months, alongside contributions from acquisitions and favorable foreign currency translations.
The company's operating income for the third quarter surged to $396.6 million, a 56.1% increase compared to $254.1 million in the prior year. This growth was driven by improved operational efficiencies and a decrease in selling, general, and administrative expenses, which fell to 15.5% of revenues from 17.3% in the previous year. Additionally, the company reported net earnings of $261.5 million for the quarter, translating to a diluted earnings per share of $3.12, compared to $2.00 in the same quarter of 2024.
Significant strategic developments included several acquisitions, with Labcorp spending $324.0 million on various businesses during the nine months ended September 30, 2025. The company also announced plans to acquire select assets from Community Health Systems and Empire City Laboratories, with expected closing dates in late 2025 and early 2026, respectively. These acquisitions are anticipated to enhance Labcorp's market presence and service offerings.
Operationally, Labcorp's Diagnostics Laboratories segment generated $2,769.6 million in revenues for the third quarter, reflecting an 8.5% increase from the previous year, while the Biopharma Laboratory Services segment reported $799.1 million, an 8.3% rise. The total volume of requisitions increased by 4.7%, indicating a solid demand for services. The company also maintained a strong cash position, with cash and cash equivalents totaling $598.1 million as of September 30, 2025, down from $1,518.7 million at the end of 2024, primarily due to increased investments and acquisitions.
Looking ahead, Labcorp anticipates continued growth driven by its strategic acquisitions and operational efficiencies. However, the company also noted potential challenges stemming from recent legislative changes, including the One Big Beautiful Bill Act, which could impact healthcare regulations and funding. Despite these uncertainties, Labcorp remains optimistic about its ability to navigate the evolving market landscape and deliver value to its shareholders.
About LABCORP HOLDINGS INC.
Labcorp Holdings Inc. is a global leader in diagnostic and biopharmaceutical laboratory services. It provides routine and specialty testing, drug development, and clinical trial support to healthcare providers, pharmaceutical companies, and researchers across approximately 100 countries. Leveraging advanced science, technology, and a broad network, it offers innovative testing solutions, supports drug approval processes, and enhances healthcare decision-making worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.